tirzepatide and diabetic retinopathy Linked to Reduced Risk of Among Obese Diabetics, Suggests Study Diabetes-Related Complications: Mechanisms and Emerging

Your dose is managed monthly by a real person

Shared decision-making between patients and clinicians, incorporating individual risk factors and preferences, remains the foundation of appropriate GLP-1 prescribing

Your provider may recommend safer dietary or electrolyte-based strategies instead

Retatrutide is expected to be a once-weekly subcutaneous injection, similar to other GLP-1 medications

For-profit takeovers of healthcare facilities may yield impressive returns for investors, but, in some cases, returns significantly accrue only at the cost of poorer patient care and outcomes

They may support recovery by signaling repair pathways, but much of the evidence is still preclinical, so benefits are best described as supportive rather than proven